AstraZeneca Pharma India share news and announcements
NSE: ASTRAZENBSE: 506820Pharmaceuticals & BiotechnologySmall Cap
Formerly Astra IDL
Last close ₹5,988.50down ₹112.50 (1.84%)BSE ₹5,988.15
Share price at the NSE close on 23 Oct 2026. Previous close ₹6,101.00.
52-week range of traded prices to 23 Oct 2026
₹5,640.00Low, 9 Oct 2026₹9,849.50High, 3 Nov 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹14,971 Cr333rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 88.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 26 May 2026
- 17.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.60%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 20.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 24.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 26 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,11847.8% delivered
AstraZeneca Pharma India share news and announcements
671 announcements, routine notices left out, newest first. Page 13 of 14.
Jul 2011
18 Jul · Dividend
July 28, 2011 will be the Dividend payout date for payment of Dividend to the members.14 Jul · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended June 30, 2011.
Jun 2011
22 Jun · Meeting
Annual General Meeting of the Company will be held on July 22, 2011. Further the Register of Members and the Share Transfer Books of the Company shall remain closed from July 9, 2011 to July 22, 2011( both days inclusive) to determine the eligible shareholders for payment of dividend for the financial year (15 Month Period) 2010-11, if declared by the shareholders at the ensuing AGM.10 Jun · Board meeting
Inter alia to consider and approve the proposal of straightening of land boundaries of factory with IDL Industries Limited.10 Jun · Management
Board of the Directors of the Company at its meeting held on May 13, 2011 has noted the appointment of Mr. Himanshu Agarwal as the CFO of the Company, with effect from May 03, 2011. The same has been approved by the Audit Committee of the Board of Directors in its meeting held on February 22, 2011.9 Jun · Dividend
Board of Directors of the Company at its meeting held on May 13, 2011 has recommended a dividend of Rs 10/- per Equity Share of a face value of Rs 2/- each for the Financial Year (15 months period) ended March 31, 2011, subject to the approval of the shareholders at the ensuing Annual General Meeting.
Apr 2011
19 Apr · Board meeting
Inter alia to consider and approve the Audited Financial Results of the Company for the quarter and financial year (15 Months) ended March 31, 2011 and to recommend dividend, if any.
Feb 2011
Jan 2011
17 Jan · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended December 31, 2010.
Oct 2010
8 Oct · Board meeting
Inter alia, to consider and approve the unaudited financial results of the Company for the quarter ended September 30, 2010.
Sep 2010
Aug 2010
Jul 2010
27 Jul · Board meeting
Board at its meeting held on July 27, 2010, has given its approval for seeking the consent/approval of the Shareholders of the Company through postal ballot to the delisting proposal initiated by AstraZeneca Pharmaceuticals, AB, Sweden, promoter of the Company, pursuant to and in accordance with Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009.13 Jul · Board meeting
Board of Directors at the meeting held on July 09, 2010, considered inter-alia seeking approval of Shareholders of the Company through postal ballot, pursuant to Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009, in connection with the delisting proposal initiated by AstraZeneca Pharmaceuticals AB, Sweden, promoter of the Company. After discussions, the Board deferred the decision on the same to the next meeting of the Board of Directors, the date of which will be intimated in due course.13 Jul · Board meeting
Inter alia, to consider and approve the un-audited financial results of the Company for the quarter and six months ended June 30, 2010.8 Jul · Board meeting
Inter alia, to consider seeking approval of Shareholders of the Company through postal ballot, pursuant to Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009, in connection with the delisting proposal initiated by AstraZeneca Pharmaceuticals AB, Sweden, promoter of the Company.
Jun 2010
29 Jun · Delisting
Pursuant to and in accordance with Regulation 8(1)(a) of the Delisting Regulations, the delisting proposal received on June 28, 2010 by the Company from AstraZeneca Pharmaceuticals AB, Sweden (AP AB), the promoter of the Company, vide AP AB's letter dated June 24, 2010 (Delisting Proposal), was considered in the Board Meeting of the Company held on June 29, 2010. As required under the said Regulation 8(1)(a) of the Delisting Regulations, the Board after considering all the relevant facts and applicable provisions contained in the Delisting Regulations, approved the Delisting Proposal.
May 2010
21 May · Meeting
(1) The Annual General Meeting of shareholders of the Company was held on May 20, 2010. The Chairman commenced the meeting at the scheduled time, shareholders attended the said meeting; (2) The audited Balance Sheet as at December 31, 2009 and the Profit and Loss Account as on that date and the Reports to the Directors and Auditors thereon were approved; (3) Dividend @ 500% i.e. Rs. 10/- per equity share of the face value Rs. 2/- each was declared and approved; (4) Mr. Francis McNamara III, Director retiring by rotation, was re-appointed as a Director of the Company; (5) Mr. Anandh Balasundaram, Director retiring by rotation, was re-appointed as a Director of the Company; (6) Mr. Luigi Felice La Corte, who was appointed as an Additional Director was appointed as a Director of the Company; (7) M/s. BSR & Co. were re-appointed as the Statutory Auditors of the Company from the conclusion of this Annual General Meeting upto the conclusion of the next Annual General Meeting and gave authorization to the Board of Directors to fix their remuneration.
Apr 2010
26 Apr · Management
Board of Directors of the Company at its meeting held on April 26, 2010 has noted the appointment of Ms. Anita Zutshi as the Chief Financial Officer of the Company w.e.f. April 03, 2010.15 Apr · Meeting
Annual General Meeting of the Company will be held on May 20, 2010. Further, the Register of Members and the Share Transfer Books of the Company shall remain closed from May 08, 2010 to May 20, 2010 ( both days inclusive) to determine the eligible shareholders for payment of dividend for the year 2009, if declared by the Shareholders at the ensuing AGM.15 Apr · Board meeting
Inter-alia, to consider and approve the unaudited financial results of the Company for the quarter ended March 31, 2010.1 Apr · Business
Press release dated April 01, 2010, titled "Bristol-Myers Squibb and AstraZeneca announce alliance to combat diabetes and launch of Onglyza (saxagliptin) in India". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2010
25 Mar · Board meeting
At the meeting of the Board of Directors of the Company held on March 25, 2010, the Directors approved the following: (1) Proposal to augment the Company's Tablet manufacturing plant and facility involving an estimated aggregate outlay of Rs.70 Crores; (2) Appointment of Mr.Luigi Felice La Corte, as an Additional Director, on the Board of Directors of the Company. Further, the Company has submitted a copy of the updated list of the Board of Directors of the Company. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Mar · Board meeting
Special meeting of the Board of Directors of the Company will be held on March 25, 2010, inter alia, to consider a proposal for augmenting the Company's existing manufacturing facility.
Feb 2010
23 Feb · Board meeting
At the Board Meeting of the Company held today i.e. February 23, 2010 the Directors approved / noted the following: (1) Change in Accounting Year : Approved the change in the accounting year of the Company from 'January-December' to 'April-March'. Accordingly, the next financial accounts and Annual Report shall be for a period of 15 months, i.e., from January 2010 to March 2011. (2) Change in Board of Directors: The Board noted the resignation of Mr. Bhasker V. Iyer, Director of the Company, with effect from February 23, 2010.23 Feb · Dividend
Board of Directors of the company in its meeting held on February 23, 2010 have recommended a dividend of Rs. 10/- per Equity Share of face value of Rs. 2/- each for the year ended December 31, 2009, subject to the approval of the shareholders at the ensuing Annual General Meeting.4 Feb · Board meeting
Inter alia to consider and approve the Audited Financial Results of the Company for the last quarter and financial year ended December 31, 2009 and to recommend dividend, if any.
Jan 2010
6 Jan · Results
Company would submit 'Audited Financial Results' for the last quarter and financial year ended December 31, 2009 within its stipulated time limits i.e. by March 31, 2010.
Oct 2009
5 Oct · Board meeting
Meeting on 27 Oct 2009: “Unaudited Financial Results for the Qtr ended Sept 30, 2009”
Jul 2009
10 Jul · Board meeting
Inter alia, to consider and approve the un-audited financial results of the Company for the quarter and half-year ended June 30, 2009.
May 2009
19 May · Meeting
Annual General Meeting of shareholders of the Company was held today i.e. May 18, 2009. The Chairman commenced the meeting at the scheduled time, 386 shareholders attended the said meeting. During the course of the meeting, the Managing Director explained the Company's proposed business growth strategy and also clarified the queries sought for by the shareholders; (2) The audited annual accounts for the year ended December 31, 2008 and the profit and loss accounts as on that date were approved; (3)Dividend @ 750% i.e. Rs. 15/- per equity share of the face value Rs. 2/- each was declared and approved;(4)M/s. BSR & Co. were re-appointed as the Statutory Auditors of the Company from the conclusion of this Annual General Meeting upto the conclusion of the next Annual General Meeting and gave authorization to the Board of Directors to fix their remuneration;(5) Mr. K. S. Shah. Director retiring by rotation, was re-appointed as a Director of the Company; and (6) Mr. Ian Brimicombe, Director retiring by rotation, was re-appointed as a Director of the Company.
Apr 2009
13 Apr · Board meeting
Meeting on 23 Apr 2009: “Unaudited Financial Results for the qtr ended March 31, 2009”8 Apr · Meeting
Annual General Meeting of the Company scheduled to be held on May 18, 2009. Further, the Register of Members and the Share Transfer Books of the Company shall remain closed from May 05, 2009 to May 18, 2009.(Both days inclusive) to determine the eligible shareholders for payment of dividend, if declared.
Feb 2009
19 Feb · Management
Vide its letter dated February 18, 2009 that: Mr. Francis McNamara has been appointed as a Director on the Board of Directors of the Company w.e.f. February 18, 2009 in the Casual Vacancy arising out of the resignation of Mr. Graham Baker who had resigned from the Board w.e.f. December 31, 2008. The updated list of the Board of Directors of the Company as on date are as follows: (1) Mr. D E Udwadia, Chairman; (2) Mr. K S Shah, Director; (3) Mr. Ian MD Brimicombe, Director; (4) Mr. Bhasker V Iyer, Director; (5) Mr. Francis McNamara, Director; (6) Mr. Anandh Balasundaram, Managing Director.18 Feb · Dividend
Board at its meeting held on February 18, 2009 has recommended a Dividend of Rs. 15/- per Equity Share of face value of Rs. 2/- each, subject to the approval of the shareholders at the ensuing Annual General Meeting scheduled to be held on May 18, 2009.3 Feb · Board meeting
Inter alia to consider and approve the Audited Financial Results of the Company for the last quarter and financial year ended December 31, 2008 and to recommend dividend, if any.
Jan 2009
23 Jan · Results
Company would submit 'Audited Financial Results' for the last quarter and financial year ended December 31, 2008 within the stipulated time limits i.e. by March 31, 2009.
Dec 2008
31 Dec · Management
Mr. Graham Baker has resigned as a Director of the Company with effect from December 31, 2008. Further the Company has submitted a copy of updated list of Board of Directors of the Company as on December 31, 2008: 1) Mr. D.E. Udwadia - Chairman & Independent Director, 2) Mr. K.S. Shah - Independent Director, 3) Mr. Ian MD Brimicombe - Director, 4) Mr. Bhasker V. Iyer - Director, 5) Mr. Anandh Balasundaram - Managing Director.3 Dec · Suspension of debentures
Members of the Exchange are hereby informed that the trading in the 8% secured fully paid-up Redeemable Non-Convertible Debentures, Symbol - ASTRAZEN, Series - N1 of AstraZeneca Pharma India Limited shall be suspended w.e.f. December 18, 2008 on account of final redemption.3 Dec · Updates
Communication dated December 2, 2008 sent to the Debentureholders. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Dec · Corporate action
The 8% secured fully paid-up redeemable non-convertible Debentures of face value of Rs. 25/- each (Bonus Debentures), issued by the Company on January 12, 2008, pursuant to the Scheme of Arrangement approved by the Hon'ble High Court of Karnataka are falling due for redemption on January 11, 2009 (Redemption Date).The Company has fixed December 26, 2008 as the Record Date for determining the entitlement of the eligible Debentureholders to receive the principal amount together with the interest accrued on the said Bonus Debentures upto the Redemption Date
Oct 2008
7 Oct · Board meeting
Meeting on 23 Oct 2008: “Unaudited financial results for qtr ended September 30, 2008”
Jul 2008
10 Jul · Board meeting
Inter alia to consider and approve the Un-audited Financial Results of the Company for the quarter and half year ended June 30, 2008.
Apr 2008
29 Apr · Meeting
At the Annual General Meeting of shareholders of the Company held on April 28, 2008 :- 1) Dividend @ 750% i.e. Rs. 15/- per equity share of the face value Rs. 2/- each was declared; 2) M/s. BSR & Co. were reappointed as the Statutory Auditors of the Company; 3) Mr. D E Udawadia, Director retiring by rotation, was re-appointed as a Director of the Company; 4) The following were appointed as Directors of the Company - i) Mr. Graham Baker. ii) Mr. Bhasker V. Iyer. 5) The appointment of Mr. Anandh Balasundaram - i) as Director of the Company; and ii) as Managing Director of the Company with effect from June 1, 2007 for a period of 5 years.16 Apr · Meeting
Notice of the Annual General Meeting of the members of the Company to be held on April 28, 2008. Further the company has submitted to the Exchange a copy of Addendum to the said notice. A copy of the same alongwith notice shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.